Chemours, DuPont and Corteva to Pay $455 Million in North Carolina PFAS Settlement — Update
By Katherine Hamilton
Chemours, DuPont de Nemours and Corteva have settled with North Carolina and 11 communities that were excluded from a previous settlement over drinking-water toxins.
The $455 million settlement resolves litigation brought by the state and local entities alleging Chemours's Fayetteville Works facility leaked PFAS "forever chemicals" and other discharges. Payments will be made over a 15-year period.
It also settles North Carolina's other claims of PFAS contamination unrelated to that site, including from the use of a fire-fighting substance called aqueous film forming foam.
The communities were previously excluded from the $1.2 billion U.S. Public Water System class settlement, which was approved in 2024.
DuPont and Corteva are responsible for half of the settlement payments, while Chemours will pay the other half, according to a previous memorandum of understanding.
Over the next 12 months, Chemours expects to pay $50 million. Of the total settlement, $18 million is attributed to alleged PFAS contamination unrelated to Fayetteville Works.
Dupont de Nemours recorded an expense of $125 million in the second quarter that reflected the pretax value of its share of cash payments related to the memorandum of understanding.
In 2019, North Carolina signed a consent order requiring Chemours to stop PFAS pollution at the Fayetteville site. Chemours said Thursday it has made substantial investments to reduce emissions of PFAS--a group of man-made chemicals that don't break down easily--at its Fayetteville site.
The settlement recognizes that several of the consent order provisions from the earlier agreement have been completed. It also establishes procedures to address certain remaining obligations relating to off-site areas, including implementing drinking-water programs.
Dupont and Corteva also plan to establish a reserve fund of $135 million that will be used as security in case Chemours fails to fulfill its obligations under the 2019 consent order.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
September 10, 2026 08:34 ET (12:34 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States